Concordia’s Photodynamic Therapy Laser Receives Premarket Approval
Concordia International Corp. said that the U.S. Food and Drug Administration has approved the Company's premarket approval application for its Photofrin 630 PDT (photodynamic therapy) Laser.
PDT with Photofrin is a light-based cancer treatment that combines the photosensitizing drug Photofrin (porfimer sodium) with a specific wavelength of laser light to attack cancer cells.
Concordia said the newly approved laser — designed for use with Photofrin to treat esophageal cancer, Barrett's Esophagus and non-small cell lung cancer — has been reengineered with new controls and peripheral systems, while maintaining the same specifications with minimal changes to the treatment procedures.
The company is also evaluating Photofrin as a potential treatment for cholangiocarcinoma, or bile duct cancer, which is a rare disease affecting approximately 2,000 to 3,000 patients annually in the U.S.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024